Proteomic analysis could be used to distinguish sporadic and genetic Alzheimer’s disease

FunGen-AD investigator Carlos Cruchaga and a team of researchers at Washington University School of Medicine in St. Louis analyzed proteins in brain tissue, cerebrospinal fluid (CSF), and plasma samples from patients with sporadic Alzheimer’s Disease (AD) or autosomal dominant AD, TREM2 variant carriers, and healthy individuals. The researchers found proteomic changes associated with forms of AD, suggesting that this type of proteomic analysis could serve as a new way to distinguish between distinct types of AD, act as a predictive model and biomarker of disease types, and identify new pathways implicated on AD. “Combined proteomics across brain tissue, CSF, and plasma can be used to identify markers for sporadic and genetically defined AD,” wrote the researchers.

The research was supported in part by FunGen-AD grant RF1 AG058501 and published in Science Translational Medicine here. You can read more about the research findings at the following links: